Inventor

=> d his

)

(FILE 'HOME' ENTERED AT 16:45:56 ON 30 MAR 2000)

FILE 'HCAPLUS' ENTERED AT 16:47:48 ON 30 MAR 2000

L1 183 S NUNOKAWA Y?/AU
L2 15506 S SUZUKI K?/AU
L3 496 S SAITOH M?/AU
L4 1 S L1 AND L2 AND L3

=> d bib abs hitstr 16

```
ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2000 ACS
     1999:626040 HCAPLUS
DN
     131:257570
     Preparation of phenylmethylbenzoquinones as NF-.kappa.B inhibitors
TI
    Nunokawa, Yoichi; Suzuki, Kenji; Saitoh,
     Masayuki
PA
     Suntory Limited, Japan
     PCT Int. Appl., 159 pp.
SO
     CODEN: PIXXD2
DT
     Patent
     Japanese
T.A
FAN.CNT 1
     PATENT NO.
                      KIND DATE
                                           APPLICATION NO. DATE
                           19990930
                                                            19990319
    WO 9948491
                                           WO 1999-JP1422
                      A1
PΙ
        W: AU, CA, CN, HU, JP, KR, US
        RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
            PT, SE
     AU 9928543
                      A1
                           19991018
                                           AU 1999-28543
                                                            19990319
PRAI JP 1998-92431
                      19980320
     WO 1999-JP1422
                     19990319
     MARPAT 131:257570
os
GI
```

$$R^{1}$$
 R^{2}
 $CH_{2}-Z-(CH_{2})_{n}+R^{4}$

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{CH}_2 \end{array} \begin{array}{c} \text{CH}_2 - \text{CH}_2 - \text{CO} \\ \text{N} \\ \text{S} \end{array}$$

The title compds. I [R1, R2 and R3 independently represent each H, C1-5 alkyl or C1-5 alkoxy; R4 represents H, hydroxymethyl, alkyl, etc.; Z is phenylene, etc.; and n is 0 to 6] are prepd. The title compd. II showed IC50 of 21 .mu.M against TNF-.alpha. prodn. in RAW 264.7 cells stimulated by lipopolysaccharide. (Stimulation of cells by lipopolysaccharide causes the activation NF-.kappa.B, followed by prodn. of TNF-.alpha.).

II

IT 11002-13-4, Angiotensinogen (protein renin substrate)
80295-48-3, Complement C4 80295-62-1, Complement factor
B 140208-23-7, Plasminogen activator inhibitor-1
143011-72-7, Granulocyte colony-stimulating factor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(gene; prepn. and effect of phenylmethylbenzoquinones with NF-.kappa.B inhibiting activity)

RN 11002-13-4 HCAPLUS

CN Angiotensinogen (protein renin substrate) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 80295-48-3 HCAPLUS

CN Complement C4 (9CI) (CA INDEX NAME)

```
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN
    80295-62-1 HCAPLUS
    Complement factor B (9CI) (CA INDEX NAME)
CN
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    140208-23-7 HCAPLUS
RN
    Proteinase inhibitor, PAI-1 (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN
    143011-72-7 HCAPLUS
    Colony-stimulating factor, granulocyte (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 125978-95-2, Nitric oxide synthase
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (iNOS-1, gene; prepn. and effect of phenylmethylbenzoquinones with
       NF-.kappa.B inhibiting activity)
    125978-95-2 HCAPLUS
    Synthase, nitric oxide (9CI) (CA INDEX NAME)
CN
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    34824-58-3
    RL: RCT (Reactant)
        (prepn. and effect of phenylmethylbenzoquinones with NF-.kappa.B
        inhibiting activity)
RN
    34824-58-3 HCAPLUS
    1,3-Dioxolane, 2-(2-bromophenyl)- (9CI) (CA INDEX NAME)
```

```
114072-73-0P 114072-77-4P 174868-90-7P
174868-93-0P 245086-27-5P 245086-28-6P
245086-29-7P 245086-30-0P 245086-31-1P
245086-32-2P 245086-33-3P 245086-34-4P
245086-35-5P 245086-36-6P 245086-37-7P
245086-39-9P 245086-40-2P 245086-42-4P
245086-44-6P 245086-45-7P 245086-46-8P
245086-47-9P 245086-48-0P 245086-49-1P
245086-50-4P 245086-51-5P 245086-52-6P
245086-53-7P 245086-54-8P 245086-55-9P
245086-56-0P 245086-57-1P 245086-58-2P
245086-59-3P 245086-60-6P 245086-61-7P
245086-62-8P 245086-63-9P 245086-64-0P
245086-65-1P 245086-66-2P 245086-67-3P
245086-68-4P 245086-69-5P 245086-70-8P
245086-71-9P 245086-72-0P 245086-73-1P
245086-74-2P 245086-76-4P 245086-77-5P
245086-80-0P 245086-82-2P 245086-84-4P
245086-86-6P 245086-88-8P 245086-90-2P
245086-91-3P 245086-92-4P 245086-93-5P
245086-94-6P 245086-95-7P 245086-96-8P
245086-97-9P 245086-98-0P 245086-99-1P
245087-00-7P 245087-01-8P 245087-02-9P
245087-03-0P 245087-04-1P 245087-05-2P
245087-06-3P 245087-07-4P 245087-08-5P
245087-09-6P 245087-10-9P 245087-11-0P
245087-12-1P 245087-13-2P 245087-14-3P
245087-15-4P 245087-16-5P 245087-17-6P
245087-19-8P 245087-20-1P 245087-21-2P
245087-22-3P 245087-23-4P 245087-24-5P
245087-25-6P 245087-26-7P 245087-27-8P
245087-28-9P 245087-29-0P 245087-30-3P
245087-31-4P 245087-32-5P 245087-33-6P
```

```
245087-34-7P 245087-35-8P 245087-36-9P
245087-37-0P 245087-38-1P 245087-39-2P
245087-40-5P 245087-41-6P 245087-42-7P
245087-43-8P 245087-44-9P 245087-45-0P
245087-46-1P 245087-47-2P 245087-48-3P
245087-49-4P 245087-50-7P 245087-51-8P
245087-52-9P 245087-53-0P 245087-54-1P
245087-55-2P 245087-56-3P 245087-57-4P
245087-58-5P 245087-59-6P 245087-60-9P
245087-61-0P 245087-62-1P 245087-63-2P
245087-64-3P 245087-65-4P 245087-66-5P
245087-67-6P 245087-68-7P 245087-69-8P
245087-70-1P 245087-71-2P 245087-72-3P
245087-73-4P 245087-74-5P 245087-75-6P
245087-76-7P 245087-77-8P 245087-78-9P
245087-79-0P 245087-80-3P 245087-81-4P
245087-82-5P 245087-84-7P 245087-85-8P
245087-86-9P 245087-87-0P 245087-88-1P
245087-89-2P 245087-90-5P 245087-91-6P
245087-92-7P 245087-93-8P 245087-94-9P
245087-95-0P 245087-96-1P 245087-97-2P
245087-98-3P 245087-99-4P 245088-00-0P
245088-01-1P 245088-02-2P 245088-03-3P
245088-04-4P 245088-05-5P 245088-06-6P
245088-07-7P 245088-08-8P 245088-09-9P
245088-10-2P 245088-11-3P 245088-12-4P
245088-13-5P 245088-14-6P 245088-15-7P
245088-16-8P 245088-17-9P 245088-18-0P
245088-19-1P 245088-20-4P 245088-21-5P
245088-22-6P 245088-23-7P 245088-24-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
   (prepn. of phenylmethylbenzoquinones as NF-.kappa.B inhibitors)
114072-73-0 HCAPLUS
Benzenepropanoic acid, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-
cyclohexadien-1-yl)methyl] - (9CI) (CA INDEX NAME)
```

$$\begin{array}{c} \text{MeO} \\ \\ \text{MeO} \\ \\ \text{O} \end{array} \begin{array}{c} \text{CH}_2 \\ \\ \text{CH}_2 - \text{CH}_2 - \text{CO}_2 \text{H} \\ \\ \end{array}$$

RN 114072-77-4 HCAPLUS

RN

CN Thiomorpholine, 4-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{Me} \end{array} \begin{array}{c} \text{CH}_2 \\ \text{CH}_2 - \text{CH}_2 - \text{C} \\ \text{C} \\ \text{C} - \text{C} \\ \text{C}$$

RN 174868-90-7 HCAPLUS

CN Morpholine, 4-[1-oxo-3-[3-[(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]propyl]- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 174868-93-0 HCAPLUS

CN Benzenepropanoic acid, 3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{MeO} \\ \text{O} \\ \text{OMe} \\ \end{array} \\ \text{CH}_2 - \text{CH}_2 - \text{CO}_2 \text{H} \\ \\ \text{CH}_2 - \text{CH}_2 - \text{CO}_2 \text{H} \\ \\ \text{OMe} \\ \end{array}$$

RN 245086-27-5 HCAPLUS

CN 2-Propenoic acid, 3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl)phenyl)- (9CI) (CA INDEX NAME)

RN 245086-28-6 HCAPLUS

CN Morpholine, 4-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl}phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{O} \\ \text{CH}_2 \\ \text{CH$$

RN 245086-29-7 HCAPLUS

CN Thiomorpholine, 4-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-, 1-oxide (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{O} \\ \text{CH}_2 \\ \text{C$$

RN 245086-30-0 HCAPLUS

CN Thiomorpholine, 4-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 $CH_$

RN 245086-31-1 HCAPLUS

CN Piperidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{O} & \text{O} \\ \text{MeO} & \text{O} & \text{CH}_2 - \text{CH}_2 - \text{C} \\ \text{Me} & \text{Me} \end{array}$$

RN 245086-32-2 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{MeO} \\ \text{O} \\ \text{OMe} \\ \end{array}$$

RN 245086-33-3 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245086-34-4 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

RN 245086-35-5 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245086-36-6 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

RN 245086-37-7 HCAPLUS

CN Morpholine, 4-[(2E)-3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

245086-39-9 HCAPLUS

Thiomorpholine, 4-[(2E)-3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEXCN

Double bond geometry as shown.

RN

245086-40-2 HCAPLUS Piperidine, 1-[(2E)-3-[4-((4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-(4,5-dimethoxy-2-methyl-3,4-(4,5-dimethoxy-2-methyCN cyclohexadien-1-yl)methyl]phenyl]-1-oxo-2-propenyl}- (9CI) (CA INDEX

Double bond geometry as shown.

245086-42-4 HCAPLUS RN

2-Propenamide, 3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1yl)methyl]phenyl]-N,N-dimethyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

245086-44-6 HCAPLUS

2-Propenamide, 3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1yl)methyl]phenyl)-N-(1-methylethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 245086-45-7 HCAPLUS

CN 2-Propenamide, 3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-N-(2-hydroxyethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 245086-46-8 HCAPLUS

CN 2-Propenamide, 3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(phenylmethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 245086-47-9 HCAPLUS

CN 2-Propenamide, 3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-N-(2-phenylethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 245086-48-0 HCAPLUS

CN Benzoic acid, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

245086-49-1 HCAPLUS RN

Morpholine, 4-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-CN yl)methyl)benzoyl]- (9CI) (CA INDEX NAME)

245086-50-4 HCAPLUS

Benzamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME) CN

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{MeO} \\ \text{O} \\ \text{OMe} \\ \end{array} \begin{array}{c} \text{C-NHPr-i} \\ \text{O} \\ \end{array}$$

RN

 $245086-51-5 \quad HCAPLUS \\ \mbox{Piperidine, } 1-[4-\{(4,5-\mbox{dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-methyl-3,$ CN yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

245086-52-6 HCAPLUS

 $Thiomorpholine, \ 4-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1,4-cy$ CN 1-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

RN 245086-53-7 HCAPLUS

CN Benzenebutanoic acid, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

RN 245086-54-8 HCAPLUS

CN Morpholine, 4-[4-[4-[4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxobutyl)- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 $CH_$

RN 245086-55-9 HCAPLUS

CN Thiomorpholine, 4-[4-[4-[4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

RN 245086-56-0 HCAPLUS

CN Piperidine, 1-[4-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

RN 245086-57-1 HCAPLUS

CN Benzenebutanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

245086-58-2 HCAPLUS RN

Piperidine, 1-[3-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-CN yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{CH}_2 - \text{CH}_2 - \text{C} \\ \text{O} \\ \text{N} \\ \end{array}$$

245086-59-3 HCAPLUS

Thiomorpholine, 4-[3-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME) CN

$$\begin{array}{c|c} \text{OMe} \\ \text{MeO} \\ \text{O} \\ \text{CH}_2 \\ \text{$$

RN

 $245086-60-6 \quad HCAPLUS \\ Morpholine, \quad 4-\{3-\{3-\{(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-methyl-3,6-dioxo-1$ CN yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} \\ \text{MeO} \\ \text{CH}_2 \\$$

245086-61-7 HCAPLUS

Benzenepropanamide, 3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-CN 1-yl)methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

245086-62-8 HCAPLUS CN

2-Propenoic acid, 3-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN

CN cyclohexadien-1-yl)methyl]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

245086-64-0 HCAPLUS

Morpholine, 4-[(2E)-3-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4cyclohexadien-1-yl)methyl]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

245086-65-1 HCAPLUS RN

2-Propenamide, 3-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl)phenyl]-N-(1-methylethyl)-, (2E)- (9CI) (CA INDEX NAME) CN

Double bond geometry as shown.

RN 245086-66-2 HCAPLUS

CN Thiomorpholine, 4-[(2E)-3-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 245086-67-3 HCAPLUS

CN Benzoic acid, 3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1yl)methyl)- (9CI) (CA INDEX NAME)

RN 245086-68-4 HCAPLUS

CN Benzamide, 3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 245086-69-5 HCAPLUS

CN Piperidine, 1-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

RN 245086-70-8 HCAPLUS

CN Morpholine, 4-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

RN 245086-71-9 HCAPLUS

CN Thiomorpholine, 4-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

RN 245086-72-0 HCAPLUS

CN Benzenepropanamide, N-(1-methylethyl)-4-[(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{Me} \end{array} \begin{array}{c} \text{CH}_2 \\ \text{CH}_2 - \text{CH}_2 - \text{C-NHPr-i} \end{array}$$

RN 245086-73-1 HCAPLUS

CN Piperidine, 1-[1-oxo-3-[4-[(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]propyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{Me} \\ \text{O} \\ \text{CH}_2 \\ \text{CH}_$$

RN 245086-74-2 HCAPLUS

CN Morpholine, 4-[1-oxo-3-(4-[(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1yl)methyl]phenyl]propyl]- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245086-76-4 HCAPLUS

CN Benzenepropanamide, N-(1-methylethyl)-3-{(2,4,5-trimethyl-3,6-dioxo-1,4cyclohexadien-1-yl)methyl}- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} & \text{O} \\ \text{II} \\ \text{CH}_2 - \text{CH}_2 - \text{C-NHPr-i} \\ \text{Me} \\ \text{Me} \end{array}$$

RN 245086-77-5 HCAPLUS

CN Piperidine, 1-[1-oxo-3-[3-[(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]propyl)- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245086-80-0 HCAPLUS

CN Benzeneacetic acid, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{MeO} \\ \text{O} \\ \text{OMe} \\ \end{array}$$

RN 245086-82-2 HCAPLUS

CN Morpholine, 4-[[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)

RN 245086-84-4 HCAPLUS

CN Piperidine, 1-[[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)

RN 245086-86-6 HCAPLUS

CN Thiomorpholine, 4-[[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{O} & \text{O} \\ \text{MeO} & \text{O} & \text{CH}_2 - \text{C} - \text{N} \end{array}$$

RN 245086-88-8 HCAPLUS

CN Benzeneacetamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{MeO} \\ \text{O} \\ \text{OMe} \\ \end{array} \\ \begin{array}{c} \text{CH}_2 \\ \text{CH}_2 - \text{C-NHPr-i} \\ \end{array}$$

RN 245086-90-2 HCAPLUS

CN Benzeneacetic acid, 3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{O} \\ \text{OMe} \end{array}$$

RN 245086-91-3 HCAPLUS

CN Piperidine, 1-[[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl}acetyl]- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 CH_2 CH_2

RN 245086-92-4 HCAPLUS

CN Thiomorpholine, 4-[(3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)

RN 245086-93-5 HCAPLUS

CN Morpholine, 4-[(3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{Me} \\ \end{array}$$

RN 245086-94-6 HCAPLUS

CN Benzeneacetamide, 3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl}-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} & \text{O} \\ \text{O} \\ \text{CH}_2 - \text{C-NHPr-i} \\ \text{OMe} \end{array}$$

RN. 245086-95-7 HCAPLUS

CN Benzenebutanoic acid, 3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

RN 245086-96-8 HCAPLUS

CN Piperidine, 1-[4-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

RN 245086-97-9 HCAPLUS

CN Thiomorpholine, 4-[4-[3-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 3 C N S

RN 245086-98-0 HCAPLUS

CN Morpholine, 4-{4-{3-{(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxobutyl}- (9CI) (CA INDEX NAME)

RN 245086-99-1 HCAPLUS

CN Benzenebutanamide, 3-((4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245087-00-7 HCAPLUS

CN 2-Propenoic acid, 3-{2-{(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 245087-01-8 HCAPLUS

Thiomorpholine, 4-[(2E)-3-[2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxo-2-propenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 245087-02-9 HCAPLUS

CN Benzenepropanoic acid, 2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl)- (9CI) (CA INDEX NAME)

RN 245087-03-0 HCAPLUS

CN Piperidine, 1-[3-[2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl}phenyl}-1-oxopropyl)- (9CI) (CA INDEX NAME)

RN 245087-04-1 HCAPLUS

CN Morpholine, 4-{3-{2-{(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl}phenyl}-1-oxopropyl]- (9CI) (CA INDEX NAME)

RN 245087-05-2 HCAPLUS

CN Thiomorpholine, 4-[3-[2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl}-1-oxopropyl)- (9CI) (CA INDEX NAME)

RN 245087-06-3 HCAPLUS

CN Benzenepropanamide, 2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 245087-07-4 HCAPLUS

CN Pyrrolidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-2-(methoxymethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 245087-08-5 HCAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-1H-inden-1-yl)-4-((4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl)- (9CI) (CA INDEX NAME)

RN 245087-09-6 HCAPLUS

CN Pyrrolidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-2-(methoxymethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 245087-10-9 HCAPLUS

CN L-Proline, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 245087-11-0 HCAPLUS

CN Piperazine, 1-(4-acetylphenyl)-4-[3-(4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} Ac & & \\$$

RN 245087-12-1 HCAPLUS

CN 4-Piperidinecarboxamide, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{O} \\ \text{CH}_2 \\ \text{CH$$

RN 245087-13-2 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_3 \\ \text{CH}_2 \\ \text{CH}_3 \\ \text{CH}_2 \\ \text{CH}_3 \\ \text$$

RN 245087-14-3 HCAPLUS

CN Piperidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-4-methyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{C} \\ \text{OMe} \end{array}$$

RN 245087-15-4 HCAPLUS

CN 3-Piperidinecarboxamide, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-l-oxopropyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{O} & \text{O} \\ \text{MeO} & \text{O} & \text{CH}_2\text{-}\text{CH}_2\text{-}\text{C} \\ \text{CH}_2\text{-}\text{CH}_2\text{-}\text{C} \\ \text{O} & \text{O} \\ \text{O} & \text{O} \end{array}$$

RN

245087-16-5 HCAPLUS
Piperidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-CN yl)methyl]phenyl]-1-oxopropyl]-2-methyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \\ \text{MeO} \\ \\ \text{CH}_2 \\ \\ \text{Me} \\ \\ \end{array}$$

245087-17-6 HCAPLUS RN

Benzenepropanamide, N-(2,3-dihydro-1H-inden-2-yl)-4-((4,5-dimethoxy-2-CN methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} O \\ NH - C - CH_2 - CH_2 \\ \end{array}$$

245087-19-8 HCAPLUS

Piperidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-CN yl)methyl]phenyl]-1-oxopropyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{O} \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{O} \\ \text{Me} \\ \end{array}$$

245087-20-1 HCAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 245087-21-2 HCAPLUS

CN 2-Piperidinemethanol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{O} \\ \text{CH}_2 \\ \text{CH$$

RN 245087-22-3 HCAPLUS

CN Benzenepropanamide, N-1,3-benzodioxol-5-yl-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

RN 245087-23-4 HCAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \\ \text{MeO} \\ \\ \text{O} \end{array} \begin{array}{c} \text{Me} \\ \\ \text{CH}_2 \\ \\ \\ \text{CH}_2 \\ \\ \text$$

RN 245087-24-5 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 245087-25-6 HCAPLUS

CN Benzenepropanamide, N-(4-benzoylphenyl)-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl)- (9CI) (CA INDEX NAME)

RN 245087-26-7 HCAPLUS

CN Benzenepropanamide, N-(4-acetylphenyl)-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{CH}_2 \\ \text{CH$$

RN 245087-27-8 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{OMe} \end{array}$$

RN 245087-28-9 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{OHe} \\ \text{OMe} \end{array}$$

RN 245087-29-0 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{CH}_2 \\ \end{array} \\ \begin{array}{c} \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{C-NH} \\ \end{array}$$

RN 245087-30-3 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{OH2} \\ \text{OH2} \\ \text{CH2} \\ \text{CH2} \\ \text{CH2} \\ \text{OH2} \\ \text{OH3} \\ \text{OH3$$

RN 245087-31-4 HCAPLUS

CN Benzenepropanamide, N-(3,5-dichlorophenyl)-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{OHe} \\ \text{OMe} \end{array}$$

RN 245087-32-5 HCAPLUS

CN Benzenepropanamide, N-(3,5-dihydroxyphenyl)-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

RN 245087-33-6 HCAPLUS

CN Benzoic acid, 4-[[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 245087-34-7 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{OMe$$

RN 245087-35-8 HCAPLUS

CN Benzenepropanamide, N-{3,5-bis(trifluoromethyl)phenyl}-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_3 \\ \text{CF}_3 \\ \text{CF}_4 \\ \text{CF}_3 \\ \text{CF}_3 \\ \text{CF}_4 \\ \text{CF}_4 \\ \text{CF}_5 \\ \text{CF$$

RN 245087-36-9 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{OMe} \\ \text{OMe} \\ \text{OMe} \end{array}$$

RN 245087-37-0 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(2-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)

RN 245087-38-1 HCAPLUS

CN 2-Piperidinecarboxylic acid, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{O} & \text{O} \\ \text{Me} & \text{O} & \text{CH}_2 - \text{CH}_2 - \text{C} - \text{N} \\ \text{Eto} - \text{C} & \text{O} \\ \text{O} & \text{O} \end{array}$$

RN 245087-39-2 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 245087-40-5 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-, ethyl ester (9CI)

(CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{O} \\ \text{O} \\ \text{CH}_2 \\ \text{CH}_$$

RN 245087-41-6 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{O} \\ \text{OMe} \end{array}$$

RN 245087-42-7 HCAPLUS

CN Quinoline, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]decahydro- (9CI) (CA INDEX NAME)

PAGE 1-A

RN 245087-43-8 HCAPLUS

CN Benzoic acid, 3-[[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \\ \text{MeO} \\ \\ \text{CH}_2 \\ \\ \text$$

RN 245087-44-9 HCAPLUS

CN Benzenepropanamide, N-[4-(cyanomethyl)phenyl]-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{CH}_2 \\ \text$$

RN 245087-45-0 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245087-46-1 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(4-pentylphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{CH}_2 \\ \end{array} \\ \begin{array}{c} \text{CH}_2 - \text{CH}_2 - \text{C} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{CH}_2 \text{ Me} \\ \text{CH}_2 \\ \end{array}$$

RN 245087-47-2 HCAPLUS

CN Benzenepropanamide, N-(3,5-dibromo-4-hydroxyphenyl)-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245087-48-3 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(3-hydroxy-4-methoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OH} \\ \text{OMe} \\ \text{OMe} \\ \text{OMe} \\ \end{array}$$

RN 245087-49-4 HCAPLUS

CN Benzenepropanamide, N-(4-butoxyphenyl)-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{OMe} \end{array}$$

RN 245087-50-7 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{O} \\ \text{OMe} \end{array}$$

RN 245087-51-8 HCAPLUS

CN Benzenepropanamide, N-(4-cyanophenyl)-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{MeO} \\ \text{O} \\ \text{OMe} \end{array}$$

RN 245087-52-9 HCAPLUS

CN Benzoic acid, 4-[{3-{4-{(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl}phenyl}-1-oxopropyl}amino}-2-hydroxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OH} & \text{OH} \\ \text{O} & \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{NH} \\ \text{OMe} \end{array}$$

RN 245087-53-0 HCAPLUS

CN Benzenepropanamide, 4-{(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl}-N-{(1S)-1-phenylethyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 245087-54-1 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[(1R)-1-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 245087-55-2 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

RN · 245087-56-3 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{MeO} \\ \text{O} \\ \text{OMe} \\ \end{array} \\ \begin{array}{c} \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{CMe}_3 \\ \\ \text{OMe} \\ \end{array}$$

RN 245087-57-4 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{MeO} \\ \text{O} \\ \text{OMe} \\ \end{array} \\ \begin{array}{c} \text{CH}_2 - \text{CH}_2 - \text{C-NH-CHEt}_2 \\ \\ \text{OMe} \\ \end{array}$$

RN 245087-58-5 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)

RN 245087-59-6 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[1-(hydroxymethyl)propyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{MeO} \\ \text{O} \\ \text{O} \\ \text{OMe} \\ \end{array} \\ \begin{array}{c} \text{CH}_2 - \text{CH}_2 - \text{C} \\ \text{NH} - \text{CH} - \text{Et} \\ \end{array}$$

- RN 245087-60-9 HCAPLUS
- CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-l-yl)methyl]-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)

- RN 245087-61-0 HCAPLUS
- CN Benzenepropanamide, 4-{(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

- RN 245087-62-1 HCAPLUS
- CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl}-N-(1-methylheptyl)- (9CI) (CA INDEX NAME)

- RN 245087-63-2 HCAPLUS
- CN Butanoic acid, 3-[[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

- RN 245087-64-3 HCAPLUS
- CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl}-N-[1-(hydroxymethyl)pentyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{Me} & \text{O} & \text{CH}_2-\text{OH} \\ \text{MeO} & \text{O} & \text{CH}_2-\text{CH} \\ \text{O} & \text{CH}_2-\text{CH}_2-\text{C-NH-CH-Bu-n} \\ \end{array}$$

RN 245087-65-4 HCAPLUS

CN Pyrrolidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

RN 245087-66-5 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl}-N-(hexahydro-2-oxo-1H-azepin-3-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A

SEARCHED BY SUSAN HANLEY 305-4053

PAGE 2-A

245087-67-6 HCAPLUS

3-Pyrrolidinol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME) CN

PAGE 1-A

PAGE 2-A

245087-68-7 HCAPLUS

Pyrrolidine, 1-[3-[4-{(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

RN 245087-69-8 HCAPLUS

CN Benzenepropanamide, N-cycloheptyl-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & \text{OMe} \\ & & \\ & \text{NH-} \text{ C-} \text{ CH}_2 \text{--} \text{ CH}_2 \\ & & \\ & & \text{OMe} \\ & & \\ & & \text{OMe} \\ & & \\ & & \text{OMe} \\ & & \\$$

RN 245087-70-1 HCAPLUS

CN Piperidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

MeO OME
$$CH_2 - CH_2 -$$

RN 245087-71-2 HCAPLUS

CN 3-Piperidinol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{O} & \text{O} \\ \text{MeO} & \text{O} & \text{CH}_2 - \text{CH}_2 - \text{C} \\ \text{Me} & \text{OH} \end{array}$$

245087-72-3 HCAPLUS RN

Piperazine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-CN yl)methyl]phenyl]-1-oxopropyl]-4-methyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{C} \\ \text{OMe} \end{array}$$

245087-73-4 HCAPLUS RN

Benzenepropanamide, N-[4-(acetylmethylamino)phenyl]-4-[(4,5-dimethoxy-2methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

RN

245087-74-5 HCAPLUS
Piperazine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-CN y1)methy1]pheny1]-1-oxopropy1]-4-{2-(2-hydroxyethoxy)ethy1]- (9CI) (CA INDEX NAME)

PAGE 1-B

— cн₂- он

RN 245087-75-6 HCAPLUS

1-Piperazinecarboxaldehyde, 4-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-CN cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Me
$$CH_2 - CH_2 - CH_2 - CH_2$$
 CHO $CH_2 - CH_2 - CH_2 - CH_2$ CHO $CH_2 - CH_2 - CH_2 - CH_2$

RN 245087-76-7 HCAPLUS

CN Piperazine, 1-acety1-4-[3-[4-[(4,5-dimethoxy-2-methy1-3,6-dioxo-1,4-cyclohexadien-1-y1)methy1)pheny1]-1-oxopropy1]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\$$

RN 245087-77-8 HCAPLUS

CN 3-Piperidinecarboxamide, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{O} & \text{O} \\ \text{MeO} & \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{C} - \text{N} \\ \text{Me} & \text{O} \end{array}$$

RN 245087-78-9 HCAPLUS

CN Quinoline, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-1,2,3,4-tetrahydro-(9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 245087-79-0 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 245087-80-3 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl)-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{CH}_2 \\ \text$$

RN 245087-81-4 HCAPLUS

CN Piperazine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-4-phenyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{O} \\ \text{OMe} \end{array}$$

RN 245087-82-5 HCAPLUS

CN Piperidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

RN 245087-84-7 HCAPLUS

CN Piperazine, 1-[3-[4-{(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl}-1-oxopropyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} N & N & C & CH_2 - CH_2 \\ \hline \\ N & N & C & CH_2 - CH_2 \\ \hline \\ OMe \\ \hline \\ OMe \\ \end{array}$$

RN 245087-85-8 HCAPLUS

CN 4-Piperidinol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-4-phenyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{O} & \text{Ph} \\ \text{O} & \text{CH}_2 - \text{CH}_2 - \text{C} - \text{N} \end{array}$$

RN 245087-86-9 HCAPLUS

CN Piperazine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{CH}_2 \\ \text$$

RN 245087-87-0 HCAPLUS

CN Piperazine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-4-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & Me \\ \hline O & N & N & C-CH_2-CH_2 & CH_2 & CH_2$$

RN 245087-88-1 HCAPLUS

CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{O} \\ \text{OMe} \end{array}$$

RN 245087-89-2 HCAPLUS

CN 4-Piperidinol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{O} \\ \text{OMe} \end{array}$$

RN 245087-90-5 HCAPLUS

CN Morpholine, 4-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl)phenyl)-1-oxopropyl)-2,6-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 245087-91-6 HCAPLUS

CN 3-Piperidinemethanol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 $CH_$

RN 245087-92-7 HCAPLUS

CN 1H-Pyrrole, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-2,5-dihydro- (9CI) (CA INDEX NAME)

RN 245087-93-8 HCAPLUS

CN Pyridine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 $CH_$

RN 245087-94-9 HCAPLUS

CN 2-Piperidineethanol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{O} \\ \text{CH}_2 \\ \text{CH$$

RN 245087-95-0 HCAPLUS

CN 4-Piperidineethanol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{O} & \text{CH}_2\text{-CH}_2\text{-OH} \\ \text{MeO} & \text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{-OH} \\ \text{Me} & \text{CH}_2\text{-CH}_2\text{-CH}_2\text{-OH} \\ \end{array}$$

RN 245087-96-1 HCAPLUS

CN 1-Piperazineethanol, 4-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ \text{MeO} & & & \\ & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

RN 245087-97-2 HCAPLUS

CN Piperazine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{CH}_2 \\ \text$$

RN 245087-98-3 HCAPLUS

CN Piperazine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 245087-99-4 HCAPLUS

CN 1,4'-Bipiperidine, 1'-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$N$$
 C CH_2 CH_2 CH_2 CH_2 CH_2 O OMe

RN 245088-00-0 HCAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME.)

Absolute stereochemistry.

RN 245088-01-1 HCAPLUS

RN 245088-02-2 HCAPLUS

CN Piperidine, 4-acetyl-1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-4-phenyl- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 $CH_$

RN 245088-03-3 HCAPLUS

CN Isoquinoline, 2-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

$$\bigcap_{N-C-CH_2-CH_2}^{O} \bigcap_{CH_2-CH_2}^{OMe} \bigcap_{Me}^{OMe} \bigcap_{Me}^{OMe}$$

RN 245088-04-4 HCAPLUS

CN 4-Piperidinone, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{CH}_2 \\ \text$$

RN 245088-05-5 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 $CH_$

RN 245088-06-6 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

RN 245088-07-7 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

RN 245088-08-8 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-hexyl- (9CI) (CA INDEX NAME)

RN 245088-09-9 HCAPLUS

CN Benzenepropanamide, N-cyclohexyl-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{MeO} & \text{Me} \\ \hline \\ \text{CH}_2 & \text{CH}_2 - \text{CH}_2 - \text{C-NH} \\ \end{array}$$

RN 245088-10-2 HCAPLUS

CN Benzenepropanamide, N-cyclopentyl-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & OMe \\ \hline O & OMe \\$$

RN 245088-11-3 HCAPLUS

CN Benzenepropanamide, N-cyclopropyl-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \overset{\circ}{\underset{\text{NH-C-CH}_2-\text{CH}_2}{\text{CH}_2-\text{CH}_2}} & \overset{\text{OMe}}{\underset{\text{Me}}{\text{OMe}}} \\ \end{array}$$

RN 245088-12-4 HCAPLUS

CN Benzenepropanamide, N-(cyclopropylmethyl)-4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & \text{OMe} \\ & & \\ & \text{CH}_2 - \text{NH} - \text{C} - \text{CH}_2 - \text{CH}_2 \\ & & \\ & & \text{OMe} \\ \end{array}$$

RN 245088-13-5 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-phenyl- (9CI) (CA INDEX NAME)

RN 245088-14-6 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245088-15-7 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

RN 245088-16-8 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \\ \text{MeO} \\ \\ \text{CH}_2 \\ \end{array} \begin{array}{c} \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{CH}_2 \\ \\ \text{CH}_2 \\ \end{array}$$

RN 245088-17-9 HCAPLUS

CN 1H-Azepine, 1-[3-(4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl)phenyl]-1-oxopropyl]hexahydro- (9CI) (CA INDEX NAME)

RN 245088-18-0 HCAPLUS

CN Benzoic acid, 4-[[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245088-19-1 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{CH}_2 \\ \end{array} \begin{array}{c} \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{C-NH} \\ \end{array}$$

RN 245088-20-4 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \text{O} \\ \text{O} \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{OMe} \\ \\ \text{OMe} \\ \end{array}$$

RN 245088-21-5 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{O} \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{OMe} \\ \end{array}$$

RN 245088-22-6 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{O} \\ \text{OMe} \\$$

RN 245088-23-7 HCAPLUS

CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{O} \\ \text{CH}_2 \\ \text{CH$$

RN 245088-24-8 HCAPLUS

CN Isoquinoline, 2-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-1,2,3,4-tetrahydro-7-methoxy- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & OMe \\ \hline N - C - CH_2 - CH_2 - CH_2 \\ \hline \end{array}$$

IT 64-04-0, Phenethylamine 75-31-0, Isopropylamine, reactions 100-46-9, Benzylamine, reactions 108-24-7, Acetic anhydride 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 123-90-0, Thiomorpholine 141-43-5, Ethanolamine, reactions 334-88-3, Diazomethane 506-59-2, Dimethylamine hydrochloride 618-51-9, 3-Iodobenzoic acid 619-58-9, p-Iodobenzoic acid 867-13-0, Triethyl phosphonoacetate 10602-01-4, 2-(4-Bromophenyl)-1,3-dioxolane 17789-14-9, 2-(3-Bromophenyl)-1,3-dioxolane 18107-18-1, Trimethylsilyldiazomethane 89048-25-9, 2,3,4,5-Tetramethoxy-6-methylbenzaldehyde 174868-88-3

RL: RCT (Reactant)
(prepn. of phenylmethylbenzoquinones as NF-.kappa.B inhibitors)
RN 64-04-0 HCAPLUS
CN Benzeneethanamine (9CI) (CA INDEX NAME)

H₂N-CH₂-CH₂-Ph
RN 75-31-0 HCAPLUS

CN 2-Propanamine (9CI) (CA INDEX NAME)

NH₂ | H₃C-СH-СH₃

RN 100-46-9 HCAPLUS CN Benzenemethanamine (9CI) (CA INDEX NAME)

 H_2N-CH_2-Ph

RN 108-24-7 HCAPLUS CN Acetic acid, anhydride (9CI) (CA INDEX NAME)

Ac- 0- Ac

RN 110-89-4 HCAPLUS CN Piperidine (7CI, 8CI, 9CI) (CA INDEX NAME)

NH

RN 110-91-8 HCAPLUS CN Morpholine (8CI, 9CI) (CA INDEX NAME)

H

RN 123-90-0 HCAPLUS CN Thiomorpholine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

(N)

RN 141-43-5 HCAPLUS CN Ethanol, 2-amino- (8CI, 9CI) (CA INDEX NAME)

H2N-CH2-CH2-OH

RN 334-88-3 HCAPLUS

CN Methane, diazo- (8CI, 9CI) (CA INDEX NAME)

 $H_2C = N \stackrel{+}{=} N^-$

RN 506-59-2 HCAPLUS

CN Methanamine, N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

H3C-NH-CH3

● HCl

RN 618-51-9 HCAPLUS

CN Benzoic acid, 3-iodo- (9CI) (CA INDEX NAME)

RN 619-58-9 HCAPLUS

CN Benzoic acid, 4-iodo- (9CI) (CA INDEX NAME)

RN 867-13-0 HCAPLUS

CN Acetic acid, (diethoxyphosphinyl)-, ethyl ester (9CI) (CA INDEX NAME)

RN 10602-01-4 HCAPLUS

CN 1,3-Dioxolane, 2-(4-bromophenyl)- (9CI) (CA INDEX NAME)

RN 17789-14-9 HCAPLUS

CN 1,3-Dioxolane, 2-(3-bromophenyl)- (9CI) (CA INDEX NAME)

RN 18107-18-1 HCAPLUS

CN Silane, (diazomethyl)trimethyl- (8CI, 9CI) (CA INDEX NAME)

 $Me_3Si-CH=N_2$

RN 89048-25-9 HCAPLUS

CN Benzaldehyde, 2,3,4,5-tetramethoxy-6-methyl- (9CI) (CA INDEX NAME)

RN 174868-88-3 HCAPLUS

CN Benzenepropanoic acid, 3-[(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1yl)methyl]- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 174868-96-3 HCAPLUS

CN Benzenepropanoic acid, 4-[(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245088-54-4 HCAPLUS

CN 2-Propenoic acid, 3-[3-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{MeO} \\ \text{OMe} \end{array} \quad \begin{array}{c} \text{CH} = \text{CH} - \text{C} - \text{OEt} \\ \text{ODMe} \\ \end{array}$$

IT 618-91-7P 619-44-3P 245088-25-9P 245088-26-0P 245088-27-1P 245088-28-2P 245088-29-3P 245088-30-6P 245088-31-7P

RN 619-44-3 HCAPLUS CN Benzoic acid, 4-iodo-, methyl ester (9CI) (CA INDEX NAME)

RN 245088-25-9 HCAPLUS
CN Benzenemethanol, .alpha.-[4-(1,3-dioxolan-2-yl)phenyl]-2,3,4,5tetramethoxy-6-methyl- (9CI) (CA INDEX NAME)

RN 245088-27-1 HCAPLUS
CN 2-Propenoic acid, 3-[4-[(acetyloxy)(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 245088-28-2 HCAPLUS

CN 2-Propenoic acid, 3-[4-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 245088-29-3 HCAPLUS

RN 245088-30-6 HCAPLUS

CN Benzenepropanoic acid, 4-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl](9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{MeO} \\ \text{OMe} \\ \end{array} \\ \text{CH}_2 - \text{CH}_2 - \text{CO}_2 \text{H} \\ \\ \text{OMe} \\ \end{array}$$

RN 245088-31-7 HCAPLUS

CN 2-Propenoic acid, 3-[4-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

RN 245088-32-8 HCAPLUS

RN 245088-33-9 HCAPLUS

CN Benzoic acid, 4-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl)- (9CI) (CA INDEX NAME)

RN 245088-34-0 HCAPLUS

CN Benzoic acid, 4-[hydroxy(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 245088-35-1 HCAPLUS

CN Benzoic acid, 4-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 245088-36-2 HCAPLUS

CN 2-Butanone, 1-diazo-4-[4-[(2,3,4,5-tetramethoxy-6methylphenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 $CH_$

RN 245088-37-3 HCAPLUS

$$\begin{array}{c} \text{OMe} \\ \text{MeO} \\ \text{MeO} \\ \text{OMe} \\ \end{array} \\ \text{CH}_2 \\ \text{CH}_2)_3 - \text{CO}_2 \\ \text{H} \\ \end{array}$$

RN 245088-38-4 HCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[[4-(4-diazo-3-oxobutyl)phenyl]methyl]-5,6dimethoxy-3-methyl- (9CI) (CA INDEX NAME)

Me
$$CH_2$$
 CH_2 CH_2

RN 245088-39-5 HCAPLUS

CN Benzoic acid, 3-[hydroxy(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]-,
 methyl ester (9CI) (CA INDEX NAME)

RN 245088-40-8 HCAPLUS

RN 245088-41-9 HCAPLUS

CN Benzoic acid, 3-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 245088-42-0 HCAPLUS

CN Ethanone, 2-diazo-1-[4-[(2,3,4,5-tetramethoxy-6-methylphenyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 MeO
 Me
 CH_2
 $C-CH$
 N_2

RN 245088-43-1 HCAPLUS

CN Ethanone, 2-diazo-1-[3-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 $C-CH=N_2$ N_2 N_3 N_4 N_4 N_5 N_5

RN 245088-44-2 HCAPLUS

RN 245088-45-3 HCAPLUS

CN 2-Butanone, 1-diazo-4-[3-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

MeO
$$CH_2$$
 CH_2 $CH_$

RN 245088-46-4 HCAPLUS

RN 245088-47-5 HCAPLUS

CN Benzenemethanol, .alpha.-(2-(1,3-dioxolan-2-yl)phenyl)-2,3,4,5-tetramethoxy-6-methyl- (9CI) (CA INDEX NAME)

RN 245088-48-6 HCAPLUS

CN Benzaldehyde, 2-[(acetyloxy)(2,3,4,5-tetramethoxy-6-methylphenyl)methyl](9CI) (CA INDEX NAME)

RN 245088-49-7 HCAPLUS

CN 2-Propenoic acid, 3-[2-[(acetyloxy)(2,3,4,5-tetramethoxy-6methylphenyl)methyl]phenyl]~, ethyl ester (9CI) (CA INDEX NAME)

RN 245088-50-0 HCAPLUS

CN 2-Propenoic acid, 3-[2-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 245088-51-1 HCAPLUS

CN 2-Propenoic acid, 3-[2-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl)phenyl)- (9CI) (CA INDEX NAME)

RN 245088-52-2 HCAPLUS

CN Benzenepropanoic acid, 2-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

245088-53-3 HCAPLUS RN

Benzenepropanoic acid, 2-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]-CN (9CI) (CA INDEX NAME)

245087-18-7P ΙT

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(reprepn. of phenylmethylbenzoquinones as NF-.kappa.B inhibitors) 245087-18-7 HCAPLUS

Piperidine, 1-[3-[4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]phenyl]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME) CN

$$\begin{array}{c|c} \text{OMe} & \text{O} & \text{O} \\ \text{MeO} & \text{O} & \text{CH}_2 - \text{CH}_2 - \text{C} \\ \text{Me} & \text{Me} \end{array}$$